Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...

BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences. The Tokyo-based drugmaker ...